´â¼­Åµ
  ÏÀʸ°ìÍ÷¡¡Ê¬³äɽ¼¨¡¡3¡¿10
´Ê°×¸¡º÷
¡¡   
¡¡
¥ê¥¹¥È¹¹¿·¡§2008/03/01(Sat) 05:13 JST
¹¹¿·¤Ï½ªÎ»¤·¤Þ¤·¤¿ ºÇ¿·¤Ï ʬ³äɽ¼¨¡¡1¡¿10

£±ÊÇɽ¼¨¤Ï¡¡¤³¤Á¤é¡£¡¡¡¡¡¡ ¤³¤Á¤é¤â¡¡ÊIJͽñ¸Ë¡¦¥ê¥¹¥È°ìÍ÷


¼ýÏ¿ÏÀʸ¡¡Á´[3889]·ïÃæ¡¡¥¢¥ë¥Õ¥¡¥Ù¥Ã¥È½ç[400]·ï

1¡¿10¤Ø¡¡ 2¡¿10¤Ø¡¡ 3¡¿10¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¤Ø¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡
¡¡
¡¡ÏÀʸ̾¶èʬ
Imatinib¡¡¡¦¡¦¡¦¥¤¥Þ¥Á¥Ë¥Ö¡¦¡¦ ¢¡30-08 ¾
 ¢¡3921GIST ¾
Imatinib Mesylate(STI571)¤¬Ãø¸ú¤·¤¿¾®Ä²Gastrointestinal Stromal Tumor½Ñ¸åÊ¢¹ÐÆâºÆÈ¯¤Î1Îã ¢¡GIST ¾
Imatinib Mesylate¤Ë¤è¤ëNeoadjuvant Therapy¤¬Í­¸ú¤Ç¤¢¤Ã¤¿°ßGIST¾ÉÎã ¢¡GIST ¾
Imatinib Mesylate¤Ë¤è¤ëNeoadjuvantÎÅË¡¤¬ÁÕ¸ú¤·½Ñ¸å·Ð²á¤òÄɤ¨¤¿µðÂç°ßGIST¤Î1Îã ¢¡GIST ¾
Imatinib(Glivec)¤È¾Ã²½´É´Ö¼Á¼ðáç ¢¡Ê¬»ÒɸŪÌô ¾
Imatinib(Glivec)¤ÈËýÀ­¹ü¿ñÀ­Çò·ìÉ ¢¡Ê¬»ÒɸŪÌô ¾
Indisetron Hydrochloride¤¬CPT-11Ͷȯ²¼Î¡¤ËÁÕ¸ú¤·¤¿1Îã ¢¡°ß´â ¾
Infliximab(¹³TNF-¦Á¥Þ¥¦¥¹¡¦¥Ò¥È¥­¥á¥é·¿¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂÎ) ¢¡¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂÎÎÅË¡ ¾
Interferon(IFN)Ê»ÍÑÆ°Ãí²½³ØÎÅË¡¤Ë¤è¤êĹ´üCR¤¬ÆÀ¤é¤ì¤¿¼ê½ÑÉÔǽ´ÎºÙ˦´â¤Î2Îã ¢¡´Î¡´â ¾
Interferon-¦ÁÅêÍ¿Ãæ¤Î¤·ì´ï¼ðáç¤Ë¤ª¤±¤ë¼«¸ÊÌȱֳØÅª°Û¾ï ¢¡Çò·ìÉ ¾
Interferon-¦ÁÊ»ÍÑ5-FluorouracilÁ´¿È²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿ºÆÈ¯´ÎºÙ˦´â¤Î1Îã29-10
Interferon-¦Â¤¬Ãø¸ú¤·¤¿É¡ÉûÉ¡¹Ð°­À­¹õ¿§¼ð Îã ¢¡Æ¬ðôÉô ¾
InterferonÎÅË¡¤ËImatinib(STI571)¤òû´ü´ÖÊ»ÍѤ·Bcr-AblÍ»¹çÀ÷¿§ÂÎÍÛÀ­ºÙ˦¤¬Ãø¸º¤·¤¿ËýÀ­¹ü¿ñÀ­Çò·ìÉ ¢¡Çò·ìÉ ¾
International Sentinel Node Society¡ÊISNS¡Ë¤ÎÀßΩ¤Èº£¸å¤ÎŸ˾ ¢¡¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀá ¾
Intra-abdominal desmoplastic small round cell tumor¤Î1Îã ¢¡£³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾
Iressa(Gefitinib)¡¡¡¦¡¦¡¦Ê¬»ÒɸŪ¼£ÎÅÌô¤ÎÎ×¾²É¾²Á¡¦¡¦ ¢¡Ê¬»ÒɸŪÌô ¾
Irinotecan Hydrochloride¤ÎÃÙȯÀ­²¼Î¡¤ËÂФ¹¤ëͽËɤθ¡Æ¤(¥±¡¼¥¹¡¦¥³¥ó¥È¥í¡¼¥ë»î¸³) ¢¡ÉûºîÍÑ Â¾
Irinotecan Ĺ´üñºÞÅêÍ¿¤ò¹Ô¤Ã¤¿ºÆÈ¯ºÆÇ³¿Ê¹Ô ¿À·Ð²ê¼ð¤Î3Îã ¢¡£¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾
Irinotecan/UFTÊ»ÍѼ£ÎŤÎÁÕ¸ú¸å¤Ë¼ê½Ñ¤ò»Ü¹Ô¤·¤¿ºÆÈ¯ÂçIJ´â¤Î2Îã ¢¡°ß´â ¾
IT²½»þÂå¤Ë¤ª¤±¤ë´â°åÎŤÎÊѲ½-IC¡¦·ÐºÑ¸ú²Ì¡¦°ÂÁ´À­¡¦ÅŻҥ«¥ë¥Æ¤Î¸úÍѤʤÉ-31-04
JCOG¤Ë¤ª¤±¤ë¿»ÜÀß¶¦Æ±»î¸³¡¡¡¦¡¦¡¦¡×COG¤ª¤è¤Ó¡×COGÉØ¿Í²Ê¥°¥ë¡¼¥×¤Ë¤Ä¤¤¤Æ ¡×COGÉØ¿Í²Ê¥°¥ë¡¼¥×¤ÎÎ×¾²»î¸³ »î¡¦¡¦ ¢¡8·îÂ裴½µ¡¡£²£¶Æü ¾
Journal Club -»ä¤¬ÃíÌܤ·¤¿ÏÀʸ31-04
L-Asparaginase¤¬°ì»þŪ¤ËÍ­¸ú¤Ç¤¢¤Ã¤¿Nasal NK/T-Cell Lymphoma ¢¡Æ¬ðôÉô ¾
l-Leucovorin,5-FUÊ»ÍÑÎÅË¡¤Î¿Ê¹Ô·ëIJ¡¦Ä¾Ä²´â¤ËÂФ¹¤ëÅêÍ¿ÊýË¡Ê̤ÎÍ­ÍÑÀ­¤Ë´Ø¤¹¤ë¸¡Æ¤ ¢¡·ëIJ´â ¾
l-Leucovorin/5-FluorouracilÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿´âÀ­Ê¢Ëì±ê¤òȼ¤¦²¼¹Ô·ëIJ´â¤Î1Îã ¢¡·ëIJ´â ¾
l-Leucovorin/5-FluorouracilÊ»ÍÑÎÅË¡¤Ë¤è¤ë½ÑÁ°²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹ÔľIJ´â¤Î1Îã ¢¡²½³ØÎÅË¡ ¾
l-LV(Levofolinate)+5-FU(5-Fluorouracil)ÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿¿Ê¹ÔÂçIJ´â¤Î1¾ÉÎã ¢¡ÂçIJ´â ¾
L-OHP(¾¦ÉÊ̾¡§¥¨¥ë¥×¥é¥Ã¥È)¤Î³«È¯¤Î·Ð°Þ ¢¡·ëIJ´â ¾
Lamivudine¤ª¤è¤ÓAdefovir ¼£ÎŤˤè¤ê´ÎºÙ˦´â¤Î¼£ÎÅÈ¿Éü¤¬²Äǽ¤Ç¤¢¤Ã¤¿B·¿ÈóÂå½þÀ­´Î¹ÅÊѤÎ1Îã ¢¡´Î¡´â ¾
Lapatinib ¡§ErbB/HER1,2¤ËÂФ¹¤ëʬ»ÒɸŪÌôºÞ¡¡¡Ý¤³¤ì¤«¤é¤ÎÆý´â¼£ÎÅÌô ¢¡8·îÂ裴½µ¡¡£²£¶Æü ¾
Lecithin ²Ã lipiodol emulsion¤òÍѤ¤¤¿´Îư̮ºÉÀòÎÅË¡¤Ë¤è¤ë¼£ÎŸú²Ì¤Î¸¡Æ¤ ¢¡´Î¡´â ¾
Lentinan¤ò´Þ¤à½Ñ¸åÊä½õÌȱֲ½³ØÎÅË¡¤Ë¤è¤ê4ǯ°Ê¾å¤Î̵ºÆÈ¯¤¬·ÑÂ³Ãæ¤Î¥ê¥ó¥ÑÀáž°ÜÍÛÀ­ÞùËì¿»½áÍÛÀ­°ß´â¤Î6¾ÉÎã ¢¡°ß´â ¾
Leucovorin/5-Fluorouracil´ÎưÃíÎÅË¡¤¬Ãø¸ú¤·¤¿ÂçIJ´â¿ȯÀ­´Îž°Ü¾ÉÎã ¢¡Å¾°ÜÀ­´Î¡´â ¾
Leucovorin¤Ë¤è¤ëModified Pharmacokinetic Modulating Chemotherapy¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ÂçIJ´â¿ȯ´Îž°Ü¤Î1Îã ¢¡ÂçIJ´â ¾
Levofolinate(l-LV),5-Fluorouracil(5-FU)¤Ë¤è¤ë´ÎưÃí²½³ØÎÅË¡¤ÈÊü¼ÍÀþÎÅË¡¤¬ÁÕ¸ú¤·¤¿Î¾ÍÕ¿ȯľIJ´â´Îž°Ü¤Î1Îã ¢¡·ëIJ´â ¾
Levofolinate¡¦5-FUÊ»ÍÑÎÅË¡¤Ë¤è¤êĹ´ü¤ÎÃø¸ú¤¬ÆÀ¤é¤ì¤Æ¤¤¤ëVirchow¤Ê¤é¤Ó¤ËÊ¢ÉôÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤòÍ­¤·¤¿¿Ê¹ÔÂçIJ´â¤Î1Îã ¢¡ÂçIJ´â ¾
Lobular endocervical glandular hyperplasia ¤Ë adenocarcinoma in situ ¤òȼ¤Ã¤¿1Îã ¢¡9·îÂ裱½µ¡Ê1Æü¡Ë ¾
Low-Dose 5-Fluorouracil/Cisplatin(FP)ÎÅË¡¤ÇComplete Response(CR)¤¬ÆÀ¤é¤ì¤¿Â¿È¯À­ÇÙ¡¦¹üž°Ü¤òÍ­¤¹¤ëstage IVB´Î´â¤Î1Îã ¢¡´Î¡´â ¾
Low-Dose 5-FU/CDDPÎÅË¡¤¬Ãø¸ú¤ò¼¨¤·Ä¹´üÀ¸Â¸¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Low-Dose 5-FU¡¦CDDPÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÃÀǹ´â½Ñ¸å¶É½êºÆÈ¯¤Î1Îã ¢¡ÃÀÆ»´â ¾
Low-Dose CDDP/TS-1Ê»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ç¹´â¿ȯÀ­´Îž°Ü¤Î1Îã ¢¡ç¹Â¡´â ¾
Low-Dose CDDP/TS-1Ê»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿Â¿È¯´Îž°Ü,ç£Å¾°Ü¤òÍ­¤¹¤ë¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Low-Dose FPÎÅË¡¤ÈÄãÍÑÎÌUFT-E¤Ë¤ÆTumor Dormancy¤¬ÆÀ¤é¤ì¤¿°ß´âºÆÈ¯¸åĹ´üÀ¸Â¸¤Î1Îã ¢¡°ß´â ¾
Low-Dose FPÎÅË¡¤Ë¤è¤ê´Îž°Ü¤¬¾Ã¼º¤·¤ÆÀÚ½ü¤¬²Äǽ¤È¤Ê¤êºÆÈ¯»þ¤ËDocetaxel¤¬ÁÕ¸ú¤·¤¿8ǯÀ¸Â¸Ãæ¤ÎStageIV°ß´â¤Î1Îã ¢¡°ß´â ¾
Low-Dose FPÎÅË¡¤Ë¤è¤êÇÙž°Ü, ½Ä³Ö¥ê¥ó¥ÑÀឰܤ¬¾Ã¼º¤·¤¿´ÎºÙ˦´â¤Î1Îã ¢¡ÇÙ´â ¾
Low-Dose PaclitaxelÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿°ß´âÈéÉæ¡¦ÇÙž°Ü¤Î1Îã ¢¡°ß´â ¾
LV/5-FU¤ò´Þ¤à°ß´â¤Î¿ºÞÊ»ÍÑÎÅË¡¡¡¡¦¡¦¡¦LV/5-FUÊ»ÍÑÎÅË¡¤Î¥á¥«¥Ë¥º¥à¤ÈÎ×¾²À®ÀÓ¡¡ LV/5-FU¤È¿ºÞ¤È¤ÎÊ»ÍÑ¡¡ ¡¡C¡¦¡¦ ¢¡°ß´â ¾
M-FLPÎÅË¡ÂÑÀ­¸å¤ËTXT/Low-Dose FPÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
MABÎÅË¡¤ÎºÆÉ¾²Á¤ÈÆâʬÈçÎÅË¡¤Î¿ÊŸ-Bicalutamide¤òÍѤ¤¤¿MABÎÅË¡¤È¿·¤¿¤ÊÆâʬÈçÎÅË¡¤Ø¤Î´üÂÔ ¢¡£··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾
MABÎÅË¡¤Îư¸þ¤ÈºÇ¶á¤Î¹Í¤¨Êý -Bicalutamide¤òÍѤ¤¤¿MABÎÅË¡¤ÎºÇ¿·É¾²Á¤òƧ¤Þ¤¨¤Æ- ¢¡Á°Î©Á£´â ¾
MALT¥ê¥ó¥Ñ¼ð¤Îʬ»ÒÉÂÍý¡¡¡¦¡¦¡¦¿·¤·¤¤¥ê¥ó¥Ñ¼ð¤ÎʬÎप¤è¤Ó¼£ÎÅ 1¡ËMALT¥ê¥ó¥Ñ¼ð¡¡2¡ËMALT¥ê¥ó¥Ñ¼ð¤Ë¸«¤é¤ì¡¦¡¦ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
Medroxy Progesterone Acetate(MPA)¤òÊ»ÍѤ·¤¿Æ°Ãí²½³ØÎÅË¡¤ò»Ü¹Ô¤·Ä¹´ü·òÂ¸Ãæ¤ÎStageIVÆý´â¤Î1Îã ¢¡Æý´â ¾
Meeting Highlights 38th Annual Meeting of the American Society of Clinical Oncology29-09
Metallic stent¤òÍѤ¤¤¿¿©Æ»´â¤ËÂФ¹¤ë²¹Ç®²½³ØÎÅË¡ ¢¡18-Supplement ¾
MethotrexateÅêÍ¿¸å¤ËµÞÀ­¿Õ¾ã³²¤òÄ褷¤¿Æ¬ðôÉô٨ʿ¾åÈé´â¤Î1Îã ¢¡£··îÂ裵½µ¡§£³£±Æü¡ÊÆü¡Ë ¾
Minocycline,OK-432,Cisplatin¤ÎÄãÍÑÎÌ3ºÞÊ»ÍѶ»¹ÐÆâÃíÆþÎÅË¡¤Ë¤è¤ë´âÀ­¶»Ëì±ê¤Î¼£Îŷи³ ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
MRCP¡¡¡¦¡¦¡¦MRCP¤ÎÆÃħ¡¿MRCP¤Î»£ÁüË¡¡¿MRCP¤ÎÀµ¾ïç¹ÃÀÆ»ÉÁ½ÐΨ¡¿ç¹´â¤ÎMRCP¿ÇÃÇ ç¹¡¦¡¦76
MRI¥ª¡¼¥À¡¼»þ¤ÎÃí°ÕÅÀ¡¡-»ºÉؿͲʰå¤Îɬ¿ÜÃμ± ¢¡MRI ¾
MRI¥¬¥¤¥É¤Ë¤è¤ë»ÒµÜ¶Ú¼ð¤ÎÅà·ë¼£ÎÅ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡29-3 ¾
MRI¥¬¥¤¥É²¼·ÐÈéŪÁÈ¿¥ÆâÅà·ë¼£ÎŤηи³¡¡¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡ ÊýË¡ Ŭ±þ¡¡ ·ë²Ì¡¡´ÎºÙ˦´â£±£°Îã¡¡¿Õ´â£·Îã¡¡»ÒµÜ¶Ú¼ð£´Îã ·ë²Ì¡¦¡¦ ¢¡28-1 ¾
MRI¥¬¥¤¥É²¼½¸Â«Ä¶²»Çȼ£ÎÅ¡¡¡¦¡¦¡¦¡¦¡¦21-3
MR¥¬¥¤¥É²¼½¸Â«Ä¶²»ÇȤòÍѤ¤¤¿Æý´â¶É½ê¼£ÎŰìÎ×¾²»î¸³BCOO3¤Î³µÎ¬°ì21-3
MTX,Ara-C¿ñÃí¤ÈDocetaxelÊ»ÍÑÎÅË¡¤Ë¤è¤êQOL¤Î²þÁ±¤òǧ¤á¤¿¿»½áÀ­¾®ÍÕ´â¤Ë¤è¤ë´âÀ­¿ñËì±ê¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
MTX/5-FU/UFT-E/CDDPÎÅË¡¸åMTX/5-FU/UFT-E/PaclitaxelÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿°ß´âÇżïÀ­¹ü¿ñ´â¾É¤Î1Îã ¢¡¹ü¿ñ¼ð ¾
MTX¡¦5-FU¸òÂåÎÅË¡¤Ë¤è¤ëƳÆþÎÅË¡¤ÈTS-1ÆâÉþ¤Ë¤è¤ëÆó¼¡¼£ÎŤ¬Ãø¸ú¤·¤¿StageIV°ß´â¸È©¼ê½ÑÎã ¢¡°ß´â ¾
Multislice Computed Tomography¤Ë¤è¤ëÆý´â¤Î¹­¤¬¤ê¿ÇÃÇ¤ÈÆý˼²¹Â¸¼ê½Ñ ¢¡8·îÂè2½µ(5Æü¡Ë ¾
NAFÊ»ÍѲ½³ØÎÅË¡(Nedaplatin+Adriamycin+5-Fluorouracil)¤¬Ãø¸ú¤·¤¿¸¶È¯ÉÔÌÀðôÉô¥ê¥ó¥ÑÀá٨ʿ¾åÈé´â¤Î1Îã ¢¡Æ¬ðôÉô ¾
National Cancer Institute-Common Toxicity Criteria(NCI-CTC Version2.0)ÆüËܸìÌõJCOGÈǤο®ÍêÀ­¤Î¸¡Æ¤ ¢¡ÉûºîÍÑ Â¾
Nedaplatin,5-FU,Leucovorin,Êü¼ÍÀþÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽ¿©Æ»´â¤Î1Îã ¢¡¿©Æ»´â ¾
Nedaplatin,5-FUÊ»ÍѲ½³ØÎÅË¡¤È¹ÐÆâ¾È¼Í¤Ë¤è¤êCR¤ÎÆÀ¤é¤ì¤¿¿Ê¹Ô¿©Æ»Ì¤Ê¬²½´â¤Î1Îã ¢¡¿©Æ»´â ¾
Nedaplatin/5-FUÊ»ÍÑÎÅË¡¤Ë¤è¤êComplete Remission(CR)¤¬ÆÀ¤é¤ì¤¿¿Ê¹Ô²¼³Ü»õÆù´â¤Î1Îã ¢¡¸ý¹Ð´â ¾
Nedaplatin¤È5-Fluorouracil¤ÎÊ»ÍÑÅêÍ¿¤¬Ãø¸ú¤ò¼¨¤·¤¿²¼³Ü»õÆù´âT4N0M0¤Î1Îã ¢¡¸ý¹Ð´â ¾
NedaplatinưÃí»þ¤ÎÅêÍ¿ÎÌ·×»»¼°¤Ë´Ø¤¹¤ë¸¡Æ¤ ¢¡²½³ØÎÅË¡ ¾
NeoadjuvantÎÅË¡¤È¤·¤ÆCPT-11¤ª¤è¤ÓCDDPÊ»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ÍñÁãCarcinosarcoma¤Î1Îã ¢¡ÍñÁã´â ¾
NeoadjuvantÎÅË¡¤È¤·¤ÆTXL¡ÜLow-Dose FPÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯´Îž°Ü¤òȼ¤¦Í©Ìç¶¹ºõ°ß´â¤Î1Îã ¢¡°ß´â ¾
NK ºÙ˦¥ê¥ó¥Ñ¼ð¡¡¡¦¡¦¡¦É¡ NK/TºÙ˦¥ê¥ó¥Ñ¼ðÉ·¿ÅªÆÃĹ¤È¿ÇÃÇ¡¡ ¸Â¶É´üÉ¡ NK/TºÙ˦¥ê¥ó¥Ñ¼ð¤Ë¤ª¤±¤ë¤³¤ì¡¦¡¦ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
NK-Enriched LAKºÙ˦¤ÎÇÝÍܤȤ½¤ÎÍ­ÍÑÀ­ ¢¡ÌȱÖÎÅË¡ ¾
NK4¤Ë¤è¤ëÀ©´â¡§´â¤ÎÅà·ë¡¦µÙ̲ºîÍѤÈÎ×¾²Æ³Æþ¤Ø¤ÎŸ˾ ¢¡Cancer Frontier Vol.4 ¾
NK4¤Ë¤è¤ëÊ¢Ëìž°ÜÍÞÀ©¤Èµ¡½ø¡¡¡¦¡¦¡¦ºàÎÁ¤ÈÊýË¡¡¡ ¡¡¥Þ¥¦¥¹¡¡ ·ë²Ì ¹Í»¡¡¦¡¦ ¢¡´âÀ­Ê¢Ëì±ê ¾
Nogitecan Hydrochloride¤Ë¤è¤ê¾É¾õ¤¬·Ú²÷¤·¤¿ºÆÈ¯¾®ºÙ˦ÇÙ´â¤Î1Îã ¢¡¾®ºÙ˦´â ¾
Non-Hodgkin's Lymphoma¤ËÂФ¹¤ëÃϸǤáÎÅË¡¤È¤·¤Æ¤Î¼«²ÈËö¾¿·ì´´ºÙ˦°Ü¿¢Ê»ÍÑÂçÎ̲½³ØÎÅË¡-Âè2Êó- ¢¡²½³ØÎÅË¡ ¾
NSAID¤Ë¤è¤ë²¼Éô¾Ã²½´É¾ã³²¤Î¿ÇÃǤȼ£ÎÅ ¢¡31-1 ¾
NSAID¤Ë¤è¤ë¿Õ¾ã³²¡¡¡¦¡¦¡¦ÌôºÞÀ­¿Õ¾ã³²¤ÎʬÎà ¿Õ¾ã³²Âкö¡¡¡¦¡¦ ¢¡31-1 ¾
NSAID¤Î¼ïÎà¤ÈÁê¸ßºîÍÑ¡¡¡¦¡¦¡¦¼ïÎà¡¡ ¡¡¥ª¥­¥·¥«¥à·Ï¡¡¥á¥í¥­¥·¥«¡¡¥â¡¼¥Ó¥Ä¥¯¡¡..... ¥×¥í¥Ô¥ª¥ó»À·Ï ¥¶¥ë¥È¡¦¡¦ ¢¡31-1 ¾
NSAlD¤Î´ðÁÃŪ¸¡Æ¤¡¡¡ÝNSAIDs¤ÎºîÍѵ¡½ø ¢¡31-1 ¾
NSAlD¤Î¼ïÎà¤ÈÁê¸ßºîÍÑ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡31-1 ¾
Office-based anesthesia¡½¡½ Ëã¿ìË¡¤ÎÁªÂò¤È°ÂÁ´À­¤Î³ÎÊÝ67-01
OK-432¤ÎÌȱֳèÀ­²½µ¡¹½¤Î²òÀÏ-ìÅ¿©,³èÀ­À®Ê¬¤ÎÍ·½Ð¤ÈTLR4¥·¥°¥Ê¥ë¤Î³èÀ­²½- ¢¡¿©À¸³è ¾
OK-432ͳÍèDNA¤Î¹³¼ðáç³èÀ­¡¡¡¦¡¦¡¦Âè26²ó´âÌȱֳ°²Ê¸¦µæ²ñ¤Ë¤ÆÈ¯É½¡¡¡¡OK-432¤ÎDNA¤Î¹³¼ðáçÌȱֳèÀ­¤Ë¤Ä¤¤¤Æ¡¡¡¡¡¦¡¦ ¢¡ÌȱÖÎÅË¡ ¾
Ondansetron Hydrochloride¤Î´â¼£ÎŤËÂФ¹¤ëÍ­ÍÑÀ­¤Î¸¡Æ¤ ¢¡ÉûºîÍÑ Â¾
Orotate Phosphoribosyltransferase(OPRT)¥¢¥Ã¥»¥¤·Ï¤Î³ÎΩ¤È°ß´âÁÈ¿¥¤Ë¤ª¤±¤ëOPRT³èÀ­ ¢¡²½³ØÎÅË¡ ¾
Oxaliplatin¡¡¡¦¡¦¡¦¼£ÌþÀÚ½üÉÔǽ¿Ê¹Ô¡¦ºÆÈ¯¤Î·ëIJ¡¦Ä¾Ä²´â¤À¤±¤¬Âоݡ¦¡¦ ¢¡·ëIJ´â ¾
Paclitaxel Bi-WeeklyÅêÍ¿¤¬Í­¸ú¤Ç¤¢¤Ã¤¿Ê¢ËìÇżï¤òȼ¤¦¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel WeeklyÅêÍ¿¤¬¸¶È¯Áã¤ËÃø¸ú¤·¤¿4·¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel WeeklyÅêÍ¿¤¬ÁÕ¸ú¤·¤¿CAFÂÑÀ­,DocetaxelÂÑÀ­Æý´â¤Î1Îã ¢¡Æý´â ¾
Paclitaxel WeeklyÅêÍ¿¤¬ÁÕ¸ú¤·¤¿º¿¹ü¾å¥ê¥ó¥ÑÀឰܤª¤è¤ÓÇÙž°Ü¤Ë¤ÆÈ¯¾É¤·¤¿ºÆÈ¯Æý´â¤Î2Îã ¢¡Æý´â ¾
Paclitaxel WeeklyÅêÍ¿¤¬Í­¸ú¤Ç¤¢¤Ã¤¿°ß´âÇÙž°Ü¤Î2Îã ¢¡°ß´â ¾
Paclitaxel WeeklyÅêÍ¿¤Ë¤ÆCR¤È¤Ê¤Ã¤¿ÂçÆ°ÀÅÌ®´Ö¥ê¥ó¥ÑÀáºÆÈ¯°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel(TXL)/CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel(TXL)¤Î½ÑÁ°Æ°ÃíÎÅË¡¤¬ÁÕ¸ú¤·¤¿¶É½ê¿Ê¹ÔÆý´â¤Î1Îã ¢¡Æý´â ¾
Paclitaxel+5'-DFURÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·ÀÚ½ü¤·ÆÀ¤¿²£¹Ô·ëIJ¿»½á¤òȼ¤¦¿Ê¹Ô°ß´â¤Î1Îã ¢¡·ëIJ´â ¾
Paclitaxel+5-FUÊ»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ÀÚ½üÉÔǽ¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel+TS-1ÅêÍ¿¤Ë¤è¤êĹ´üÀ¸Â¸Ãæ¤Î°ß´â½Ñ¸åÊ¢ËìºÆÈ¯¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
Paclitaxel,5-FluorouracilÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤ÆQOL¤ò²þÁ±¤·Æâáñ²½¤ËÀ®¸ù¤·¤¿¿Ê¹ÔºÆÈ¯°ß´â¤Î1Îã ¢¡£²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
Paclitaxel,5-FUÊ»ÍѲ½³ØÎÅË¡¤Ë¤è¤ê´âÀ­Ê¢Ëì±ê¤¬²þÁ±¤·¤¿°ß´âºÆÈ¯¾ÉÎã ¢¡¥¹¥­¥ë¥¹ ¾
Paclitaxel/CarboplatinÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÍñÁã´âIV´ü¤È¿Ê¹ÔľIJ´â¤Î½ÅÊ£´â¤Î1Îã ¢¡·ëIJ´â ¾
Paclitaxel/CarboplatinÎÅË¡¤ò¹Ô¤Ã¤¿¥Ñ¡¼¥­¥ó¥½¥óɹçÊ»ÍñÁã´â¤Î1Îã ¢¡ÍñÁã´â ¾
Paclitaxel/CDDP WeeklyÅêÍ¿¤¬ÁÕ¸ú¤·º¬¼£ÀÚ½ü²Äǽ¤È¤Ê¤Ã¤¿4·¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡²½³ØÎÅË¡ ¾
Paclitaxel/TS-1Ê»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿Ç٤δâÀ­¥ê¥ó¥Ñ´É¾É¤òȼ¤¦¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel¡¦Carboplatin(TJ)²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿»ÒµÜÂδâ¤ÎÇÙž°Ü¾ÉÎã ¢¡»ÒµÜÂδâ ¾
Paclitaxel¡¦TS-1Ê»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Ê¢ËìÇżï¤òÍ­¤¹¤ë°ß´â¤Î1Îã ¢¡£··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾
Paclitaxel¤ÈTS-1¤ÎÊ»ÍѤ¬Í­¸ú¤Ç¤¢¤Ã¤¿°ß´â¥ê¥ó¥ÑÀឰܤÎ1Îã ¢¡°ß´â ¾
Paclitaxel¤Ë¤è¤ë²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¶»ÉôCT¾åÀþ°Ý²½¤òÄ褷¤Ê¤¬¤é½Ì¾®¤·¤¿Stage IV¿Ê¹ÔÇÙÁ£´â¤Î1Îã ¢¡¶»Á£¼ð ¾
Paclitaxel¤ÎWeeklyÅêÍ¿¤¬Í­ÍѤǤ¢¤Ã¤¿°ß´âºÆÈ¯¤Ë¤è¤ë´âÀ­¿´Ç¹±ê¤Î1Îã ¢¡£²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
Paclitaxel¤ÎWeeklyÅêÍ¿¤Ç¿´ê÷±ÕÀ©¸æ¤¬ÆÀ¤é¤ì¤¿ÇÙÁ£´â´âÀ­¿´Ëì±ê¤Î1Îã ¢¡ÇÙ´â ¾
Paclitaxel¤ÎWeeklyÅêÍ¿¤Ë¤Æ´âÀ­Ê¢¿å¤¬´°Á´¾Ã¼º¤·¤¿°ß´â¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
Paclitaxel¤ÎWeeklyÅêÍ¿¤Ë¤ÆÃøÌÀ¤Ê¼ðáç¤Î½Ì¾®¤òǧ¤á¤¿¿Ê¹ÔÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡È󾮺Ù˦´â ¾
Paclitaxel¤ÎWeeklyÅêÍ¿¤Ë¤è¤ê°ß¶É½êÀÚ½ü¸å¤ÎÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀáºÆÈ¯¤¬´°Á´¾Ã¼º(CR)¤·¤¿TS-1¼£ÎÅÄñ¹³À­°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel¤ÎÄãÍÑÎÌWeeklyÅêÍ¿¤ÈAnastrozole¤ÎÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹ÔÆý´â¤Î3Îã ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
Paclitaxel¤ÎÊ¢¹ÐÆâ¤ÈÁ´¿È¤ÎÅêÍ¿¤ÇÁá´ü¤Ë´âÀ­Ê¢¿å¤¬¾Ã¼º¤·¤¿°ß´â¤Î1Îã ¢¡°ß´â ¾
Paclitaxel¤ÎÊ¢¿åÃæ¤Ø¤Î°Ü¹Ô¤ò¸¡Æ¤¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡°ß´â ¾
PaclitaxelÅêÍ¿¤Ë¤è¤êÊ¢ËìÇżï¤Ë¤è¤ë¥¤¥ì¥¦¥¹¤È¿ȯ´Îž°Ü¤ËÁÕ¸ú¤Î¤ß¤é¤ì¤¿AFP»ºÀ¸°ß´â¤Î1Îã ¢¡´âÀ­Ê¢Ëì±ê ¾
PaclitaxelÊ¢¹ÐÆâÅêÍ¿¤ÈÀÅÌ®ÆâÅêÍ¿¤Î¼ðáçÆâPyNPase³èÀ­ÊѲ½¤Î¼Â¸³Åª¸¡Æ¤ ¢¡ÂçIJ´â ¾
PancoastÇÙ´â¤Î¼£ÎÅÀ®ÀÓ¡¡¡¡¡¦¡¦¡¦Âоݤª¤è¤ÓÊýË¡¡¡13Îã PancoastÇÙ´â¡¡ ·ë²Ì¡¡½ÑÁ°¾È¼Í¡¡ ¹Í»¡¡¡¡¦¡¦ ¢¡ÇÙ´â ¾
Peritonectomy¤òÍѤ¤¤¿Ê¢ËìÇżï¤Î½¸³ØÅª¼£ÎÅ ¢¡´âÀ­Ê¢Ëì±ê ¾
Peritonectomy¤òÍѤ¤¤¿Ê¢ËìÇżï¤Î½¸³ØÅª¼£ÎÅ ¢¡8·îÂ裳¡Ý£²¡Ê£±£¸Æü¡Ë ¾
Peritonectomy¤òÍѤ¤¤¿Ê¢ËìÇżï¤Î½¸³ØÅª¼£ÎÅ ¢¡£³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾
Peritonectomy¤òÍѤ¤¤¿Ê¢ËìÇżï¤Î½¸³ØÅª¼£ÎÅ ¢¡¤½¤Î¾¤Î´â ¾
Peritonectomy¤òÍѤ¤¤¿Ê¢ËìÇżï¤Î½¸³ØÅª¼£ÎÅ ¢¡66-08 ¾
Peritonectomy¤òÍѤ¤¤¿Ê¢ËìÇżï¤Î½¸³ØÅª¼£ÎÅ ¢¡51-10 ¾
PET-CT¤Î´â¿ÇÃǤؤαþÍÑ¡¡¡¦¡¦¡¦¾ÉÎã¡§¾å°öƬ´â¡¦Çٴ⡦ç¹Â¡´â¡¦»ÒµÜÆâËì´Ö¼ÁÆù¼ð¡¦Ä¾Ä²´â¡¦°­À­¥ê¥ó¥Ñ¼ð¡¦¡¦ ¢¡ÇÙ´â ¾
PET¤Ë¤è¤ë´â¿ÇÃǤÎÎ×¾²Å¬±þ¡¡¡¦¡¦¡¦FDG-PET¤Î¸½¾õ¡¡ ¸¡¿Ç¤ÈPET ´ÕÊÌ¿ÇÃÇ¡¡ É´ü¿ÇÃÇ¡¡ ´â¤ÎºÆÈ¯¿ÇÃÇ¡¡ ¡¦¡¦ ¢¡Cancer Frontier Vol.4 ¾
PET¤Î´â¿ÇÃÇ¡¦¼£ÎŤؤαþÍÑ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡¸¡ºº ¾
PET¤òÍѤ¤¤¿¼ðáç¿ÇÃǤοÊÊâ¡¡¡¦¡¦¡¦Îò»Ë¤È¸¶Íý¡¡ ¼ðáçFDG-PET¤ÎÎ×¾²±þÍÑ¡¡ ¡¡Æ¬ðôÉô´â¡¡¹Ã¾õÁ£´â¡¡ÇÙ´â¡¡¿©Æ»´â¡¡ ¡¦¡¦ ¢¡²èÁü¿ÇÃÇ Â¾
PET¸¡ºº¤Î²ÝÂê¤Èº£¸å¤ÎŸ˾¡¡¡¦¡¦¡¦¥Ý¥¸¥È¥í¥óÃÇÁØ»£±ÆË¡¡ÊPET)¡¡¡¡ £±¡ËPET¸¡ºº¤Î²ÝÂê¡¡ £²¡ËPET¤òÍѤ¤¤¿¸¡¡¦¡¦ ¢¡¸¡ºº ¾
Pharmacokinetic Modulating Chemotherapy(PMC)-CPT-11ÎÅË¡(Modified PMC)¤¬Ãø¸ú¤·¤¿ÂçIJ´â´Îž°Ü¾ÉÎã¤Î1Îã ¢¡ÂçIJ´â ¾
Pharmacokinetic Modulating Chemotherapy/CPT-11ÎÅË¡¤¬Ãø¸ú¤·¤¿Ä¾Ä²´â¿ȯÀ­´Îž°Ü¤Î1Îã ¢¡·ëIJ´â ¾
Pharmacokinetic Modulating Chemotherapy¤ÈLow-Dose CPT-11¼£ÎŤ¬Í­ÍѤǤ¢¤Ã¤¿¹ü¡¦´Î¡¦¶»Ë잰ܤòȼ¤Ã¤¿·ëIJ´â¤Î1Îã ¢¡·ëIJ´â ¾
Photo Quiz 183¡¡¡¦¡¦¡¦¾ÉÎã¡¡ ¡¡4ºÐ¡¡ÃË»ù¡¡¸åÊ¢Ëì¥ê¥ó¥Ñ´É¼ð ·Ð²á ²òÀ⡦¡¦ ¢¡£´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾
PMC(Pharmacokinetic Modulating Chemotherapy)ÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Î¡¦ÇÙž°Ü¤òȼ¤¦ÀÚ½üÉÔǽ¿Ê¹ÔľIJ´â¤Î1Îã ¢¡ÂçIJ´â ¾
PMCÎÅË¡¤¬ÁÕ¸ú¤·,¤½¤Î·Ð²áÃæ¤Ë·ìÀ¶5-FUÇ»Å٤άÄ꤬²Äǽ¤Ç¤¢¤Ã¤¿Ä¾Ä²´â½Ñ¸å´ÎÇÙž°Ü¤Î1Îã ¢¡·ëIJ´â ¾
PPAR¦Ã¤ÈÂçIJ´â¡¡Å¾¼Ì°ø»Ò¤È¾Ã²½´É´â¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡£¸·î£±Æü ¾
ProteasomeÁ˳²ºÞ¡¡¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡ ¡¡1.³«È¯¤ÎÎò»Ë¤È¥³¥ó¥»¥×¥È¡¡ ¡¡2.ºîÍѵ¡½ø¤ÈɸŪ¡¡ ¡¡3.Bort¡¦¡¦ ¢¡Ê¬»ÒɸŪÌô ¾
PSA¤ª¤è¤Ó´ØÏ¢¥Ñ¥é¥á¡¼¥¿¤Î¼è¤ê°·¤¤¡¡¡¦¡¦¡¦Á°Î©Á£´â¤ò¤á¤°¤ë¥³¥ó¥»¥ó¥µ¥¹¤ÈÏÀÅÀ¡¦¡¦ ¢¡Á°Î©Á£´â ¾
PSK¤Ë¤è¤ëÂçIJ´â½Ñ¸åÊä½õÌȱֲ½³ØÎÅË¡¤ÎResponderȽÄê¤Ë¤ª¤±¤ë¥¨¥Ó¥Ç¥ó¥¹ ¢¡ÌȱÖÎÅË¡ ¾
PyNPase,DPD¤«¤é¤ß¤¿¥ê¥ó¥ÑÀáž°ÜÍÛÀ­Æý¤¬¤ó¤Î5'-DFURÅêÍ¿¸ú²Ì¤Î²ÄǽÀ­ ¢¡Æý´â ¾
QOL¤è¤ê¤ß¤¿»ÒµÜ´â¤Î¼£ÎÅ -»ÒµÜðô´â¡¡¡¦¡¦¡¦¹üÈ×Æâ¼«Î§¿À·Ð²¹Â¸ ÍñÁ㲹¸¡¡ Ç¥ÕÔÀ­²¹Â¸¡¦¡¦ ¢¡£¸·îÂè1½µ(£¶Æü¡Ë ¾
QOL¤ò¹Íθ¤·¤¿¿Ê¹Ô¤ª¤è¤ÓºÆÈ¯ÉؿͲʴâ¤ËÂФ¹¤ëBiweekly PaclitaxelÅêÍ¿¤Î»î¤ß ¢¡£··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾
QOL°Ý»ý¤ËTS-1ÅêÍ¿¤¬Í­¸ú¤Ç¤¢¤Ã¤¿¿Ê¹Ô¡¦ºÆÈ¯°ß´â¤Î2Îã ¢¡°ß´â ¾
RFA¤È¾¼£ÎŤÎÊ»ÍÑ ¡Ý ´Î´â ¥é¥¸¥ªÇȼ£ÎŤκÇÁ°Àþ ¢¡´Î¡´â ¾
RFA¤Î¸½¶·¤Èº£¸å¡¡¡¦¡¦¡¦¡¦¡¦22²ó¡¡Âç²ñ
RFÁÈ¿¥Æâ²Ã²¹¤Ë¤è¤ë°­À­¿À·Ðç±¼ð¥Ø¤Îͼ¡¼¥²¥Æ¥£¥ó¥° ¢¡21-Supplement ­µ ¾
RFÁÈ¿¥Æâ²Ã²¹Ë¡¤Î³«È¯¤ÈÎ×¾²±þÍѰìÁÈ¿¥Æâ¾È¼Í¤È¤ÎÊ»ÍѰ젢¡18-Supplement ¾
Rituximab¡¡¡¦¡¦¡¦Ê¬»ÒɸŪ¼£ÎÅÌô¤ÎÎ×¾²É¾²Á¡¦¡¦ ¢¡Ê¬»ÒɸŪÌô ¾
Rituximab Ê»ÍÑ¿ºÞÊ»ÍѲ½³ØÎÅË¡(R-CHOPÎÅË¡)¤Ë¤è¤ê´°Á´´²²ò¤òÆÀ¤¿ÇÙ·ì´ÉÆâBºÙ˦À­¥ê¥ó¥Ñ¼ð¤Î1Îã ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
Rituximab(¥ê¥Ä¥­¥µ¥ó)¡¡¡¦¡¦¡¦BºÙ˦¥ê¥ó¥Ñ¼ð¡¡¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΡ¦¡¦ ¢¡²½³ØÎÅË¡ ¾
Rituximab(¹³CD20¥Þ¥¦¥¹¡¦¥Ò¥È¥­¥á¥é·¿¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂÎ) ¢¡¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂÎÎÅË¡ ¾
¡¡

¥Ú¡¼¥¸¤ÎÀèÆ¬¤ËÌá¤ë¡¡¡¡ 1¡¿10¤Ø¡¡ 2¡¿10¤Ø¡¡ 3¡¿10¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¤Ø¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡

¡¡Ãøºî¸¢Ë¡¤Î´Ø·¸¾å¡¢Í½¹ð¤Ê¤¯Ê£¼Ì¥µ¡¼¥Ó¥¹¤òÄä»ß¤·¤¿¤êÃøºî¸¢ÎÁ¤ò²þÄꤹ¤ë¾ì¹ç¤¬Í­¤ê¤Þ¤¹¡£